*β-Hydroxysteroid Dehydrogenase Type 1 inhibition in Idiopathic Intracranial Hypertension: a double-blind randomized controlled trial.

*Keira Markey PhD¹, *James Mitchell MBChB¹,²,³, *Hannah Botfield PhD⁴, Ryan S Ottridge⁵, Tim Matthews FRCPophth⁶, Anita Krishnan MBChB⁷, Rebecca Woolley⁵, Connar Westgate¹,², Andreas Yiangou MBChB¹,²,³, Pushkar Shah FRCPophth⁸, Caroline Rick PhD⁵, Natalie Ives⁵, Angela E Taylor PhD¹,², Lorna C Gilligan PhD¹,², Carl Jenkinson PhD¹,², Wiebke Arlt MD¹,², William Scotton MBChB¹,²,³, Rebecca Fairclough D.Phil⁹, Rishi Singhal FRCS¹⁰, Paul M Stewart MD¹¹, Jeremy W Tomlinson PhD¹², Gareth G Lavery PhD¹,², Susan P Mollan FRCPophth¹,⁶, Alexandra J Sinclair PhD¹,²,³

1. Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom (UK);
2. Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, B15 2TH, UK;
3. Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, B15 2WB, UK;
4. Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, United Kingdom (UK);
5. Birmingham Clinical Trials Unit, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK;
6. Birmingham Neuro-Ophthalmology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, B15 2WB, UK;
7. Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, L9 7LJ, UK;
Short running title: Idiopathic Intracranial Hypertension Drug Trial

8. Institute of Neurological Sciences, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, G51 4TF, UK;

9. Emerging Innovations Unit, Scientific Partnering and Alliances, IMED Biotech Unit, AstraZeneca, Cambridge, CB2 0SL, UK;

10. Upper GI Unit and Minimally Invasive Unit, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B9 5SS, UK;

11. Medical School, University of Leeds, Leeds, LS2 9JT, UK;

12. Oxford Centre for Diabetes, Endocrinology & Metabolism (OCDEM), NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Headington, Oxford, OX3 7LJ, UK.

*joint authorship

**Corresponding author:** Alexandra Sinclair, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; a.b.sinclair@bham.ac.uk ORCID iD 0000-0003-2777-5132

Word count: 3403
Abstract

Treatment options for idiopathic intracranial hypertension are limited. The enzyme 11β-hydroxysteroid dehydrogenase type 1 has been implicated in regulating cerebrospinal fluid secretion, and its activity is associated with alterations in intracranial pressure in idiopathic intracranial hypertension. We assessed therapeutic efficacy, safety and tolerability, and investigate indicators of in vivo efficacy of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor AZD4017 compared to placebo in idiopathic intracranial hypertension. A multicenter, UK, 16-week phase II randomized, double-blind, placebo-controlled trial of 12-weeks treatment with AZD4017 or placebo was conducted. Women aged 18 to 55 years with active idiopathic intracranial hypertension (>25cmH2O lumbar puncture opening pressure and active papilledema) were included. Participants received 400mg twice daily of oral AZD4017 compared to matching placebo over 12-weeks. The outcome measures were initial efficacy, safety and tolerability. The primary clinical outcome was lumbar puncture opening pressure at 12 weeks analysed by intention-to-treat. Secondary clinical outcomes were symptoms, visual function, papilledema, headache and anthropological measures. In vivo efficacy was evaluated in the central nervous system and systemically. 31 subjects (mean age 31.2 (SD=6.9) years and BMI 39.2 (SD=12.6) kg/m²) were randomized to AZD4017 (n=17) or placebo (n=14). At 12 weeks, lumbar puncture pressure was lower in the AZD4017 group (29.7 cmH2O) compared with placebo (31.3 cmH2O), but the difference between groups was not statistically significant (mean difference: -2.8, 95% confidence interval: -7.1-1.5; p=0.2). An exploratory analysis assessing mean change in lumbar puncture pressure within each group found a significant decrease in the AZD4017 group (mean change: -4.3 cmH2O (SD=5.7); p=0.009) but not in the placebo group (mean change: -0.3 cmH2O (SD=5.9); p=0.8). AZD4017 was safe, with no withdrawals related to adverse effects.
Nine transient drug-related adverse events were reported. One serious adverse event occurred in the placebo group (deterioration requiring shunt surgery). *In vivo* biomarkers of 11β-hydroxysteroid dehydrogenase type 1 activity (urinary glucocorticoid metabolites, hepatic prednisolone generation and CSF cortisone to cortisol ratios) demonstrated significant enzyme inhibition. This is the first phase 2 randomized controlled trial in idiopathic intracranial hypertension evaluating a novel therapeutic target. AZD4017 was safe, well-tolerated and inhibited 11β-hydroxysteroid dehydrogenase type 1 activity *in vivo*. Possible clinical benefits were noted in this small cohort. A longer, larger study would now be of interest.

**Key words**: idiopathic intracranial hypertension, 11β-hydroxysteroid dehydrogenase type 1, papilloedema, headache, phase 2, randomized controlled trial
Abbreviations:

11β-HSD1: 11β-hydroxysteroid dehydrogenase type 1 inhibitor
5αTHF: 5α-tetrahydrocortisol
ACTH: Adrenocorticotropic hormone
BBB: Blood brain barrier
CP: Choroid Plexus
CSF: Cerebrospinal fluid
DHEAS: Dehydroepiandrosterone sulfate
E: Cortisone
F: Cortisol
HPA: Hypothalamic pituitary adrenal
ICP: Intracranial pressure
IIH: Idiopathic Intracranial Hypertension
LC-MS/MS: Liquid chromatography-tandem mass spectrometry
OCT: Optical coherence tomography
PMD: Perimetric mean deviation
RCT: Randomised Controlled Trial
RNFL: Retinal nerve fibre layer
THE: Tetrahydrocortisone
THF: Tetrahydrocortisol
VA: Visual acuity
Introduction

Idiopathic intracranial hypertension (IIH) is a debilitating condition characterized by raised intracranial pressure (ICP), papilledema with risk of permanent visual loss, (Mollan et al., 2018b) and chronic headaches which reduce quality of life. (Mulla et al., 2015) IIH predominately affects obese women between the ages of 25-36 years with a distinct androgen excess signature recently identified. (Daniels et al., 2007; Markey et al., 2016; O'Reilly et al., 2019) Incidence is increasing in line with escalating worldwide obesity rates. (Mollan et al., 2018a)

Surgical treatment is recommended when vision rapidly declines, (Mollan et al., 2014; Mollan et al., 2018c) but the majority of patients (93%) are managed conservatively. (Hoffmann et al., 2018; Mollan et al., 2018a; Mollan et al., 2018b) Dietary interventions are an effective treatment, (Sinclair et al., 2010a) however, meaningful and sustained weight loss is difficult to achieve. (Colquitt et al., 2014; Manfield et al., 2017) Pharmacotherapy in IIH is limited, (Piper et al., 2015) with only two previous randomized controlled trials (RCTs) in IIH previously reported, both evaluating acetazolamide. (Ball et al., 2011; Committee et al., 2014) New treatment options are therefore urgently required. (Mollan et al., 2018b)

We have previously demonstrated that the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is expressed and active in the choroid plexus (CP) to amplify cortisol availability and acts to regulate cerebrospinal fluid (CSF) production. (Gathercole et al., 2013) (Sinclair et al., 2007; Sinclair et al., 2010c) In patients with IIH, resolution of disease (reduced ICP, improvements in papilledema and headaches) was associated with reduced 11β-HSD1 activity, (Sinclair et al., 2010a; Sinclair et al., 2010c) with a study suggesting that inhibition of 11β-HSD1 with a non-selective inhibitor lowered intraocular pressure. (Rauz et al., 2003)
Importantly, $11\beta$-HSD1 expression and activity is dysregulated in obesity. (Sandeep et al., 2005) (Wake and Walker, 2004)

Selective inhibitors of $11\beta$-HSD1 have been developed as treatments for obesity, hepatic steatosis, metabolic syndrome and type 2 diabetes. (Boyle, 2008; Stefan et al., 2014) Based on these data, $11\beta$-HSD1 could represent a therapeutic target for lowering CSF pressure. AZD4017 is a highly selective, fully reversible, competitive $11\beta$-HSD1 inhibitor. It has been tested over short time intervals in healthy males (9 days), and abdominally obese subjects (10 days), and found to be safe and tolerable. (AstraZeneca, 2000-[01 March 2017]-a, b, c, d, 2000-[01 March 2017].) The ability of AZD4017 to penetrate the blood-brain-barrier (BBB) is not established; however, the CP lies outside the BBB and consequently can be targeted directly following oral administration. (Davson, 1966; Eftekhari et al., 2015)

We hypothesised that inhibition of $11\beta$-HSD1 could be therapeutically beneficial in IIH. To test this we conducted a multicenter phase 2 double-blind, placebo-controlled RCT in IIH using the selective $11\beta$-HSD1 inhibitor AZD4017, aiming to assess therapeutic efficacy, safety and tolerability, and investigate \textit{in vivo} systemic and central nervous system efficacy.
Methods

Study Conduct
The study was conducted from March 2014 to December 2016 in three UK hospitals. The National Research Ethics Committee York and Humber-Leeds West gave ethical approval (13/YH/0366). All patients provided written informed consent in accordance with the declaration of Helsinki. Detailed clinical trial methodology has been published. (Markey et al., 2017a)

Study Population
Women (18-55 years) were eligible if they had a clinical diagnosis of active IIH meeting the updated, modified Dandy criteria (ICP>25cmH2O and active papilledema) and normal brain imaging (including magnetic resonance venography or CT with venography) at recruitment (for detailed eligibility criteria see Suppl. Table 1). (Friedman et al., 2013; Markey et al., 2017b)

Study design
A 16-week phase II, double-blind placebo-controlled RCT with a 12-week dosing duration and 4-week follow-up off drug.

Randomization and Blinding
Participants were allocated to either drug or placebo. Patients were allocated a trial number randomly by phone, using block-of-6 randomization. Participants and investigators were masked to treatment allocation during the trial.

Intervention
An oral selective 11β-HSD1 inhibitor, AZD4017, at 400mg twice daily for 12-weeks, compared to a matched placebo. Trial dosing was added to existing therapy for IIH, other drugs were maintained at a fixed dose throughout the study.
Assessments

Participants completed follow-up assessments at 1, 2, 3, 4, 6, 8, 10, 12 and 16 weeks (Figure 1A).

Clinical assessments

The primary outcome for clinical efficacy was the difference in ICP between AZD4017 and placebo, as measured by LP at 12 weeks. Secondary outcomes included: IIH symptoms, visual function (visual acuity (VA) measured using LogMAR (log of the minimum angle of resolution), perimetric mean deviation (PMD) using Humphrey 24-2 central threshold automated perimetry and contrast sensitivity assessed by MARs charts (Mars Perceptrix, USA)), papilledema, headache associated disability and anthropological measures. Papilledema was evaluated using spectral domain optical coherence tomography (OCT; Spectralis, Heidelberg Engineering) to quantify the peripapillary retinal nerve fibre layer (RNFL) average and maximal values. Papilledema was graded from fundus photographs by three masked neuro-ophthalmologists using the Frisén classification (0 denotes no papilledema to grade 5 severest papilledema).(Frisen, 1982) Headache was evaluated through the headache impact test-6 disability questionnaire (HIT-6), headache severity (verbal rating score 0 to 10), frequency (days per month), duration and analgesic use (days per month).(Bayliss et al., 2003) Pill counting at each visit determined drug compliance.

In the original grant application and early versions of the protocol, the primary outcome measure was stated as the change in ICP between baseline and 12 weeks. Following adoption of the study by the Birmingham Clinical Trials Unit, the primary outcome was changed to ICP at 12 weeks, with adjustment for baseline ICP in the analysis. This change was made blind to any data analysis.
Safety and Tolerability

Adverse events and safety bloods were monitored (timeline Figure 1A) including renal function (urea, creatinine and electrolytes), liver function (aspartate transaminase, alanine transferase, bilirubin, alkaline phosphatase, gamma-glutamyl transferase), thyroid function (thyroid stimulating hormone, free thyroxine) and creatine kinase. Hypothalamic pituitary adrenal (HPA) axis activity was monitored (cortisol, adrenocorticotropic hormone (ACTH), dehydroepiandrosterone sulfate (DHEAS), testosterone, androstenedione, follicle stimulating hormone, luteinizing hormone, estradiol and progesterone).

Glucocorticoid and AZD4017 blood and CSF levels

Samples were collected and stored at -80°C. Cortisol and cortisone levels in serum and CSF were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) at the University of Birmingham, as previously described. Plasma and CSF AZD4017 levels were quantified by an external laboratory (Alderley Analytical, Knutsford, UK).

In vivo systemic 11β-Hydroxysteroid Dehydrogenase activity

Global 11β-HSD1 activity was evaluated through quantification of 24 hour urinary glucocorticoid metabolites, by LC-MS/MS. (Sagmeister et al., 2018) 11β-HSD1 activity was inferred from the ratio of (5α-tetrahydrocortisol + tetrahydrocortisol):tetrahydrocortisone ((5αTHF+THF):THE) alongside a stable ratio of total urinary cortisol (F): total urinary cortisone (E) reflecting 11β-HSD2 activity. (Tomlinson and Stewart, 2001)

In vivo hepatic 11β-Hydroxysteroid Dehydrogenase activity

Inhibition of hepatic 11β-HSD1 activity was informed by measuring first-pass metabolism of 10mg of oral prednisone to prednisolone. Serum prednisone and prednisolone were measured
every 20 minutes over 4 hours using LC-MS/MS.(Richards et al., 2012; Hassan-Smith et al., 2015)

**Ex vivo adipose 11β-Hydroxysteroid Dehydrogenase activity**

Subcutaneous adipose biopsies (100-150 mg distributed to triplicate experiment) incubated in media (Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (ThermoFisher, Rugby, UK) at room temperature with 100 nM cortisone (Sigma-Aldrich, Dorset, UK), with three media controls (without adipose) for 24 hours. Steroid conversion was quantified using LC-MS/MS.(Juhlen et al., 2015; Mooij et al., 2015)

**In vitro adipose 11β-Hydroxysteroid Dehydrogenase inhibition by AZD4017**

Subcutaneous and omental adipose explants (1-2g in triplicate) were obtained from IIH patients undergoing bariatric surgery. Samples were incubated with either 2000nM, 200nM or 20nM of AZD4017 and 100nM of cortisone alongside three controls (without AZD4017) for 24 hours. Steroid conversion was quantified using LC-MS/MS.(Juhlen et al., 2015; Mooij et al., 2015)

**Statistical Analysis**

Analysis of the clinical data was based on the full analysis set according to the statistical analysis plan (Supplemental document). Analysis was conducted using intention-to-treat with data from all available randomized participants used. The primary comparison was between AZD4017 versus placebo at 12 weeks. The majority of data was continuous, so groups were compared using linear regression models with baseline measurements included as a covariate in the model. IIH symptom data was binary and was analyzed using log-binomial models with baseline symptom included as a covariate in the model. The primary analysis of visual data included data from both eyes, using a linear mixed model with participant included as a random effect. We also analyzed data from the most affected eye at baseline as defined by
PMD. (Friedman et al., 2014) Statistical significance was set at p<0.05, with no adjustment for multiple comparisons made. Clinical data was analyzed using SAS (version 9.4) and STATA (version 14).

Analysis of laboratory data was performed using SPSS (version 24, IBM, New York, USA). An unpaired t-test was used for normally distributed data (Mann-Whitney U test for non-parametric data). For related groups, either the paired t-test or Wilcoxon signed-rank test was used for parametric and non-parametric data respectively. We reported means and standard deviations (medians and ranges for non-parametric data).

**Sample Size**

To detect a difference between groups of 14% in ICP (assuming a standard deviation of 10% for ICP) with 90% power and two-sided alpha=0.05, required 12 participants per group. Allowing for 20% drop-out, we aimed to recruit 30 participants.

**Data availability**

The trial is registered at Clinicaltrials.gov NCT02017444; European Clinical Trials Database (EudraCT Number: 2013-003643-31). The data that support the findings of this study are available from the corresponding author, upon reasonable request.
Results

31 participants were recruited; 17 were randomized to AZD4017 and 14 to placebo (Figure 1B). Baseline characteristics demonstrate a cohort of IIH patients with active disease were recruited (Table 1).

Clinical Outcomes

Primary Clinical Outcome

At 12 weeks, the mean ICP was 29.7 cmH2O (SD=5.2) in the AZD4017 group compared with 31.3 cmH2O (SD=6.7) in the placebo group (adjusted mean difference: -2.8 cmH2O, 95% confidence interval (CI): -7.1-1.5; p=0.2) (Figure 2A). An exploratory analysis assessed the mean change in ICP within each group. ICP decreased from 33.7 (SD=6.3) at baseline to 29.7 cmH2O (SD=5.2) at 12 weeks in the AZD4017 group (mean change: -4.3 cmH2O (SD=5.7); p=0.009) and from 32.7 (SD=4.8) to 31.3 cmH2O (SD=6.7) in the placebo group (mean change: -0.3 cmH2O (SD=5.9); p=0.8 (Figure 2B,C).

Secondary Clinical Outcomes

At weeks 12 and 16, there were no statistically significant differences between the two treatment groups in IIH symptoms (Suppl. Table 2). At 12 and 16 weeks, the Humphrey Visual Field Analyzer PMD (worst eye) was not significantly different between groups (adjusted mean difference at 12 weeks: 0.3dB, 95% CI: -2.0-2.7, p=0.8) (Figure 2D, E, F; Table 2, Suppl. Table 3). However, within group analysis showed that the PMD improved from -6.1 dB (SD=5.4) at baseline to -3.4 dB (SD=3.2) (mean change 2.7 dB (SD=4.3), p=0.04) at 12 weeks in the AZD4017 group and from -3.4 dB (SD=6.8) to -2.2 dB (SD=3.1) (mean change 0.3 dB (SD=6.0), p=1.0) in the placebo group. There were also no statistically significant differences
between groups at either 12 or 16 weeks in visual acuity, contrast sensitivity, OCT average and maximal RNFL (Table 2; Figure 2G,H,I maximum RNFL, Figure 2J,K,L average RNFL, Suppl. Table 3). At 12 weeks, the mean Frisén grade in the worst eye was 1.56 (SD=0.96) in the AZD4017 group and 2.25 (SD=0.87) in the placebo group (adjusted mean difference: -0.7, 95% CI:-1.4-0.3; p=0.06).

All headache outcomes were not statistically significantly different between AZD4017 and placebo at weeks 12 or 16 (Suppl. Table 4). There were also no statistically significant differences in any of the anthropological outcomes (BMI, waist:hip ratio).

Safety and Tolerability

Study medication was well tolerated with participants in both arms taking on average 98% of the total 168 study medication doses (mean doses taken were 164 (range 146 – 168) and 165 (range 158-168) in the AZD4017 and placebo group respectively). There were no participant withdrawals due to adverse effects. Nine adverse events (in 6 participants) were deemed related to AZD4017, none were serious and 3 were due to non-clinically relevant fluctuations in serum cortisol. Adverse events are shown in Suppl. Table 5. One serious adverse event was reported in the placebo arm and deemed unrelated (fulminant deterioration in IIH necessitating CSF shunting one day post-randomization).

No differences were noted between treatment groups for the safety blood tests (Suppl. Table 6). As expected, there was a rise in the HPA stimulatory hormone, ACTH, over 12 weeks in the AZD4017 group (mean difference at 12 weeks: 12.36ng/l, 95% CI: -0.03-24.74). There was no difference in serum cortisol, testosterone or androstenedione, although serum DHEAS, a marker of adrenal androgen production was higher at 12 weeks in the AZD4017 group (mean difference
In vivo assessments

Blood and CSF levels of AZD4017 and glucocorticoids

AZD4017 concentrations were detected in the serum after one week of treatment and sustained at week 12 (n=6). The presence of AZD4017 in the CSF was 0.5% that of the serum (Suppl. Table 7). No AZD4017 was detected in the placebo group at any time point. There was no correlation between serum or CSF drug levels and LP pressure (serum: $r=0.03; p=1.0$; CSF: $r=-0.2; p=0.7$) or visual field mean deviation (serum: $r=-0.2; p=0.7$; CSF: $r=-0.04; p=0.9$).

Serum and CSF cortisol and cortisone were examined in the placebo and AZD4017 groups at baseline and at 12 weeks. The serum cortisol:cortisone ratio was not significantly different between arms at weeks 0 ($p=0.6$) and 12 ($p=0.5$) (Figure 3A). The CSF cortisol:cortisone ratio did not differ between arms at baseline ($p=0.9$); however, at week 12 there was a significant decrease in the CSF cortisol:cortisone in the AZD4017 group compared to placebo ($p=0.002$), and the AZD4017 group between baseline and 12 weeks ($p=0.03$) (Figure 3B), implying local 11β-HSD1 activity can regulate CSF glucocorticoid exposure.

In vivo systemic 11β-Hydroxysteroid Dehydrogenase activity

The urinary (5αTHF+THF):THE glucocorticoid metabolite ratio reflective of systemic 11β-HSD1 activity was significantly reduced in AZD4017 vs. placebo groups at week 1 (0.16±0.04 versus 0.90±0.36, $p<0.0001$) and week 12 (0.27±0.29 versus 0.90±0.28; $p<0.0001$). By contrast, the ratios did not differ between the two treatment groups at baseline ($p=0.6$) and 4 weeks after treatment cessation (week 16).
the end of treatment (week 16, \( p=0.8 \)). 11\( \beta \)-HSD type 2 activity as assessed by urinary cortisol over cortisone remained unchanged and similar in both groups throughout the 12 weeks of treatment (\( p=0.6 \)). These data imply that AZD4017 was effective at inhibiting 11\( \beta \)-HSD1 (Figure 3C). No correlation was found between the change in (5\( \alpha \)THF+THF):THE and ICP (\( r=0.1; \ p=0.7 \)) or PMD (\( r=0.2; \ p=0.4 \)).

**Hepatic 11\( \beta \)-Hydroxysteroid Dehydrogenase activity**

The placebo group had robust capacity to generate prednisolone following oral prednisone at both baseline and after 12 weeks. The baseline prednisolone generation curve for the AZD4017 group was indistinguishable from the placebo curve; however at 12 weeks the AZD4017 group were essentially unable to generate prednisolone (Figure 3D,E), indicating effective inhibition of hepatic 11\( \beta \)-HSD1 activity. Area under the curve analysis of the mean time points at 12 weeks showed significantly impaired prednisolone generating capacity for AZD4017 vs. placebo (228±99 vs 1738±142; \( p<0.0001 \)), an 85.9\% reduction (\( p<0.0001 \)) in overall prednisolone generating capacity after 12 weeks (Figure 3D,E). There was no correlation between the change in the area under the curve for prednisolone and ICP (\( r=0.1; \ p=0.8 \)) or PMD (\( r=0.4; \ p=0.2 \)).

**Adipose 11\( \beta \)-Hydroxysteroid Dehydrogenase activity**

While AZD4017 effectively inhibited hepatic 11\( \beta \)-HSD1, we were unable to show impaired capacity to generate cortisol from cortisone in explanted subcutaneous adipose biopsies. At baseline and following 12 weeks of oral AZD4017, there was no significant change in total cortisol vs. placebo (9.0±5.6 vs 12.4±4.9 nmol; \( p=0.3 \)) or percentage conversion of cortisone to cortisol (23±14 vs 27±18 \%; \( p>0.99 \)) (Figure 3F). However, AZD4017 was able to significantly
inhibit 11β-HSD1 activity when added to ex vivo adipose explants from subcutaneous and omental depots. 20nM AZD4017 significantly impaired conversion of cortisone to cortisol (>70% vs. control), 200nM onwards was sufficient to effectively block cortisol generation, particularly in the subcutaneous depot (Figure 3G,H).
Discussion

We report the first phase 2 RCT assessing 11β-HSD1 inhibitor AZD4017 for the treatment of IIH. We have shown some possible clinical benefit for AZD4017, and that it was well tolerated and safe. We found evidence for effective in vivo 11β-HSD1 inhibition.

Our primary hypothesis stated that 11β-HSD1 inhibition in IIH patients would reduce CSF secretion and lower ICP while being safe and tolerable following 12 weeks of treatment. ICP was the primary clinical outcome measure, representing the hallmark of the disease driving clinical sequelae. At 12 weeks, although ICP was lower in the AZD4017 group compared to placebo, the difference between groups was not statistically significant. Exploratory analyses of the mean change within groups found a significant improvement in ICP in the AZD4017 group between baseline and 12 weeks, but not in the placebo group. Previous trials have noted that ICP reduction below the cut off of 25 cmH2O is not universally required to translate into resolution of IIH clinical features.(Sinclair et al., 2010b) A minimal clinically important change in ICP in IIH has not been determined, and establishing one would be useful for future trials.

The visual field perimetric assessment is another clinically meaningful measure and has been selected as the primary outcome measures in previous IIH trials. We found no difference between groups in PMD at 12 weeks, however, there was significant improvement over time in the AZD4017 arm but not in the placebo arm. This may reflect the pragmatic recruitment of all degrees of PMD at enrolment whilst other trials have enrolled a selected cohort (e.g. -2 to -5 dB).(Wall et al., 2014) Additionally, his small trial was not powered to determine significant in the secondary outcome measures.
Headache is a key disabling feature in IIH. (Mulla et al., 2015) We did not detect differences between the groups in any of the headache assessments at 12 weeks, although data from the patient completed HIT-6 favoured the AZD4017 group. Evaluating the effect of AZD4017 on headache measures over a longer treatment duration would be of interest.

Previous trials showed that 11β-HSD1 inhibition leads to adaptive changes in HPA stimulatory hormone ACTH and the adrenal androgen precursor DHEA. Our data support these findings, but with no significant change in downstream effector hormones (cortisol and testosterone).

In vivo evaluation of our patients demonstrated that AZD4017 was a highly effective systemic and hepatic 11β-HSD1 inhibitor, in line with previous studies using 11β-HSD1 inhibitors in humans (Schwab et al., 2017); (Courtney et al., 2008). Systemic efficacy may modify metabolic aspects of IIH with indirect benefits on ICP. (Hornby et al., 2018)

While AZD4017 effectively inhibited 11β-HSD1 when applied to subcutaneous and omental adipose tissue explants, we were unable to prove inhibition in vivo, and propose that 11β-HSD1 activity recovers over the assay period once removed from AZD4017, a reversible competitive inhibitor.

Blood-brain-barrier AZD4017 penetrance was low, with levels in the CSF 0.5% those of plasma levels, but were associated with reduced CSF cortisol:cortisone ratio suggesting that 11β-HSD1 may contribute to cortisol availability in the CSF. The unchanged serum cortisol:cortisone is likely reflective of HPA axis set-point.
Limitations

We were unable to directly evaluate 11β-HSD1 inhibition at the choroid plexus, the tissue responsible for CSF secretion. We have evaluated efficacy of other IIH drugs using rodent ICP monitoring models, (Botfield et al., 2017; Scotton et al., 2018) but AZD4017 is only effective in humans and primates, thus limiting our ability to evaluate its action in rodent models. The trial duration was likely too short. A duration of 12 weeks was chosen for evaluation of safety and tolerability and represented the longest duration of dosing to date with AZ4017. This may not have been sufficient for meaningful evaluation of clinical outcomes with other IIH RCTs evaluating drugs over a 6 month period. (Committee et al., 2014) The enrolment criteria for the study were deliberately broad allowing inclusion of a spectrum of IIH patients with active disease and ensuring generalizability of results; however, this did not allow evaluation in disease subgroups such as those with mild visual loss vs. those with severe irreversible visual loss. Finally, the sample size (31 participants) is small which may have limited meaningful evaluation of clinical measures and the trial was not design to establish significant changes in the secondary clinical outcome measures.

Conclusions

This is the first phase II study evaluating the novel pharmacological therapy AZD4017 in IIH. We demonstrate safety, tolerability and provide strong in vivo evidence for effective 11β-HSD1 inhibition. There was a significant reduction in ICP in the AZD4017 and not the placebo group.
over the treatment duration (exploratory within group analysis); however, the primary analysis evaluating the difference between groups at 12 weeks did not reach statistical significance. The data suggest that 11β-HSD1 inhibition may have utility for reducing the effects and consequences of raised ICP in patients with IIH. Further evaluation of these therapeutic strategies in this disabling disease, for which few useful medical options exist, would be worthwhile.
Contributions

KM, JM & HB made major contributions to the acquisition, and interpretation of data; and drafting of the work.

RW & NI made substantial contributions to the clinical statistics and undertook the data analysis of the clinical data.

SM, RO, TM, AK, PS, CR, WS & AY made substantial contributions to the clinical data acquisition and drafting of the work.

AT, LG, CJ & WA were responsible for steroid analysis in serum, CSF and tissue by LC-MS/MS analysis and contributed to the drafting of the work.

RS & CW made substantial contributions to the adipose data acquisition and drafting of the work.

RF made a substantial contribution to study safety and delivery.

PS, JT & GL were involved in conceptualization of the hypothesis and drafting and revision of the work.

AS conceptualized the hypothesis and led on study design, oversight, interpretation of data and drafting of the work.

All authors approved the final version to be submitted for review.

Conflict of Interest Disclosures: No authors contributing have a conflict of interest in the subject matter.

Funding: The trial was funded by the Medical Research Council, UK (MR/K015184/1). AS is funded by an NIHR Clinician Scientist Fellowship (NIHR-CS-011-028). AstraZeneca provided
this study, through their chosen CMO (Almac), with the study medication AZD4017 and placebo.

Acknowledgements

We acknowledge Birmingham Clinical Trials Unit for trial coordination, data management and clinical data analysis. We thank Peter Nightingale, Statistician, NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2TH, UK, for help with the exploratory analyses. We acknowledge the support of the National Institute of Health Research Clinical Research Network (NIHR CRN) and the nurses and staff of the NIHR/Wellcome Trust Clinical Research Facilities where IIH:DT was performed. The views expressed in this publication are those of the authors and not necessarily those of the MRC, NIHR or the Department of Health. We thank AstraZeneca for the AZD4017 compound and for their helpful advice, specifically from Madeleine Brady, K. Jane Escott, Rebecca J Fairclough, Alison Holt, James Sylvester, Lorraine C. Webber and Chris Wilks. We acknowledge Almac Group, UK for the randomization.
Short running title: Idiopathic Intracranial Hypertension Drug Trial

References


AstraZeneca. A phase IIa study to assess the tolerability, safety and efficacy of AZD4017 for raised intra-ocular pressure. 2000-[01 March 2017]-b [cited; Available from: http://clinicaltrials.gov/show/NCT01173471


Short running title: Idiopathic Intracranial Hypertension Drug Trial


Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, Nowakowska K, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a
rationale for increasing abiraterone exposure or combining with MDV3100. Cancer research 2012; 72(9): 2176-82.


Figure legends:

Figure 1: Participant visits (A) and CONSORT diagram (B). GC, glucocorticoids, CSF, cerebrospinal fluid, ICP, intracranial pressure.

Figure 2. Clinical outcomes following treatment with AZD4017 and placebo for 12 weeks and then 4 weeks after stopping treatment.

(A) Absolute LP pressure. (B) Change in LP pressure. (C) Percentage of patients with better, same or worse LP pressure at 12 weeks. (D) Absolute visual field mean deviation (dB). (E) Change in visual field mean deviation. (F) Percentage of patients with better, same or worse visual field mean deviation at 12 weeks. (G) Absolute maximum optical coherence tomography (OCT) retinal nerve fibre layer (RNFL) height (µm). (H) Change in maximum OCT RNFL height. (I) Percentage of patients with better, same or worse maximum OCT RNFL height at 12 weeks. (J) Average OCT RNFL height (µm). (K) Change in average OCT RNFL height. (L) Number of patients with better, same or worse average OCT RNFL height at 12 weeks. Data is presented as mean ± 95% confidence index. *<0.05, **<0.01.

Figure 3. In vivo and ex vivo analysis of 11β-HSD activity after 12 weeks treatment with either AZD4017 or placebo

(A) Serum cortisol:cortisone ratio. (B) CSF cortisol:cortisone ratio. (C) Urinary 11β-HSD1 activity ((5α-THF+THF):THE) at weeks 0, 1, 12 and 16. (D) Change in prednisolone area under the curve (AUC) (see E). (E) Hepatic 11β-HSD1 activity (mean blood prednisolone concentration after conversion from prednisone) over 4 hours. (F) Subcutaneous adipose 11β-HSD1 activity (percentage change from cortisone to cortisol) ex vivo. (G) Ex vivo subcutaneous adipose (H) Omental adipose 11β-HSD1 activity (cortisol production from cortisone) after 24
32 hours incubation with either 0, 20, 200 or 2000 nM of AZD4017 in vitro. Data presented as mean±SD. * p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001
## Table 1: Baseline characteristics and ophthalmic measurements

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n=14)</th>
<th>AZD4017 (n=17)</th>
<th>Total (n=31)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in years (SD)</td>
<td>32.4 (8.0)</td>
<td>30.1 (5.9)</td>
<td>31.2 (6.9)</td>
</tr>
<tr>
<td>Ethnicity (number (%))</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White British</td>
<td>13 (93)</td>
<td>16 (94)</td>
<td>29 (94)</td>
</tr>
<tr>
<td>Asian/Asian British – Pakistani</td>
<td>0 (0)</td>
<td>1 (6)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Asian/Asian British – Other Asian</td>
<td>1 (7)</td>
<td>0 (0)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Number on acetazolamide (%)</td>
<td>4 (29)</td>
<td>6 (35)</td>
<td>10 (32)</td>
</tr>
<tr>
<td>Opening LP pressure, cmH2O (SD)</td>
<td>32.7 (4.8)</td>
<td>33.7 (6.3)</td>
<td>33.3 (5.6)</td>
</tr>
<tr>
<td>Weight, kg (SD)</td>
<td>108.4 (42.3)</td>
<td>97.9 (21.3)</td>
<td>102.6 (32.3)</td>
</tr>
<tr>
<td>BMI (weight (kg)/ height (m²) (SD)</td>
<td>41.2 (16.6)</td>
<td>37.3 (7.2)</td>
<td>39.2 (12.6)</td>
</tr>
<tr>
<td>HIT-6 score (SD)</td>
<td>63.4 (8.1)</td>
<td>63.8 (8.2)</td>
<td>63.6 (8.0)</td>
</tr>
<tr>
<td>IIH Symptoms (number (%))</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>14 (100)</td>
<td>16 (94)</td>
<td>30 (97)</td>
</tr>
<tr>
<td>Visual loss</td>
<td>8 (57)</td>
<td>4 (24)</td>
<td>12 (39)</td>
</tr>
<tr>
<td>Pulsatile tinnitus</td>
<td>13 (93)</td>
<td>12 (71)</td>
<td>25 (81)</td>
</tr>
<tr>
<td>Diplopia</td>
<td>5 (36)</td>
<td>7 (41)</td>
<td>12 (39)</td>
</tr>
<tr>
<td>Transient visual obscurations</td>
<td>6 (43)</td>
<td>6 (35)</td>
<td>12 (39)</td>
</tr>
<tr>
<td>Perimetric mean deviation, dB (SD)</td>
<td>-3.4 (6.8)</td>
<td>-6.1 (5.4)</td>
<td>-4.8 (6.1)</td>
</tr>
<tr>
<td>Log visual acuity (SD)</td>
<td>0.13 (0.22)</td>
<td>0.08 (0.23)</td>
<td>0.10 (0.22)</td>
</tr>
<tr>
<td>Log contrast sensitivity</td>
<td>N=12</td>
<td>N=13</td>
<td>N=25</td>
</tr>
<tr>
<td></td>
<td>1.63 (0.16)</td>
<td>1.63 (0.22)</td>
<td>1.63 (0.19)</td>
</tr>
<tr>
<td>OCT, thickness in μm (SD)</td>
<td>N=10</td>
<td>N=17</td>
<td>N=27</td>
</tr>
<tr>
<td>Average retinal nerve fibre layer</td>
<td>158.4 (83.0)</td>
<td>152.0 (68.7)</td>
<td>154.4 (72.8)</td>
</tr>
<tr>
<td>Maximum retinal nerve fibre</td>
<td>290.0 (102.4)</td>
<td>320.2 (117.2)</td>
<td>309.6 (110.4)</td>
</tr>
<tr>
<td>Frisén Grading, number (%)</td>
<td>N=11</td>
<td>N=16</td>
<td>N=27</td>
</tr>
<tr>
<td>1</td>
<td>2 (18)</td>
<td>4 (25)</td>
<td>6 (22)</td>
</tr>
<tr>
<td>2</td>
<td>5 (45)</td>
<td>9 (56)</td>
<td>14 (52)</td>
</tr>
<tr>
<td>3</td>
<td>3 (27)</td>
<td>0 (0)</td>
<td>3 (11)</td>
</tr>
<tr>
<td>4</td>
<td>1 (9)</td>
<td>2 (13)</td>
<td>3 (11)</td>
</tr>
<tr>
<td>5</td>
<td>0 (0)</td>
<td>1 (6)</td>
<td>1 (4)</td>
</tr>
</tbody>
</table>
Visual data is from the worst eye only. BMI, body mass index; dB, decibels; HIT-6, headache impact test -6; LP, lumbar puncture; OCT, optical coherence tomography; SD, standard deviation.
### Table 2: Visual function and optic nerve head at baseline and week 12

<table>
<thead>
<tr>
<th>Worse Eye</th>
<th>Baseline Mean value (SD)</th>
<th>Week 12 Mean value (SD)</th>
<th>Adjusted mean difference at 12 weeks (95% C.I)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo</td>
<td>AZD4017</td>
<td>Placebo</td>
<td>AZD4017</td>
</tr>
<tr>
<td>Visual Acuity LogMAR</td>
<td>0.13 (0.22)</td>
<td>0.08 (0.23)</td>
<td>0.09 (0.18)</td>
<td>0.06 (0.15)</td>
</tr>
<tr>
<td>Contrast Sensitivity</td>
<td>1.63 (0.16)</td>
<td>1.63 (0.22)</td>
<td>1.66 (0.12)</td>
<td>1.65 (0.15)</td>
</tr>
<tr>
<td>Perimetric Mean Deviation</td>
<td>-3.4 (6.8)</td>
<td>-6.1 (5.4)</td>
<td>-2.2 (3.1)</td>
<td>-3.4 (3.2)</td>
</tr>
<tr>
<td>OCT RNFL Average (μm)</td>
<td>158.4 (83.0)</td>
<td>152.0 (68.7)</td>
<td>143.2 (78.7)</td>
<td>139.7 (56.3)</td>
</tr>
<tr>
<td>OCT Maximal RNFL (μm)</td>
<td>290.0 (102.4)</td>
<td>320.2 (117.2)</td>
<td>277.0 (133.1)</td>
<td>305.5 (122.3)</td>
</tr>
<tr>
<td>Average Frisén grading</td>
<td>2.27 (0.90)</td>
<td>2.19 (1.17)</td>
<td>2.25 (0.87)</td>
<td>1.56 (0.96)</td>
</tr>
</tbody>
</table>

All measures shown in the table are of worst eye. Negative values in the adjusted mean difference between treatment arms favour AZD4017. C.I: confidence interval; OCT: optical coherence tomography; RNFL: retinal nerve fibre layer; SD: standard deviation.

### Supplemental files

Supplemental File 1: Additional data
### A

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Measure</th>
<th>Weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><em>Adverse events and compliance</em></td>
<td></td>
</tr>
<tr>
<td>Safety</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Blood tests</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Pregnancy test</em></td>
<td></td>
</tr>
<tr>
<td>Laboratory</td>
<td><em>Serum and CSF</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>GC and drug levels</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>24 hour urine</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Prednisolone measurements</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Subcutaneous adipose explants</em></td>
<td></td>
</tr>
<tr>
<td>Clinical</td>
<td><em>LP</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Visual function tests</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Papilloedema assessment</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Headache assessments</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Body mass index</em></td>
<td></td>
</tr>
</tbody>
</table>

### B

#### Tertiary referral hospital sites:
- University Hospitals Birmingham
- NHS Foundation Trust
- The Walton Centre NHS Foundation Trust
- NHS Greater Glasgow & Clyde

**Screened (n=43)**
- Not randomised (n=12)
  - 3 not eligible (reasons unknown)
  - 3 declined
  - 4 not eligible due to other medication
  - 1 not eligible due to thyroid dysfunction
  - 1 failed screening due to low ICP

**Randomised (n=31)**

**Allocated to Placebo (n=14)**
- Lost to follow-up (n=1)
  - Withdrawn 1 day after randomisation as found to be ineligible due to pre-existing thyroid disease
  - Withdrawn (n=1)
    - Withdrew due to rapid disease progression requiring CSF shunting

**Allocated to 11β-HSD1 inhibitor (n=17)**

**Follow-up**
- No withdrawals or lost to follow ups

**Analysis**
- Analysed for primary outcome (n=16)
  - (n=1 participant missing ICP at week 12)